Invivyd reported a 25% year-over-year and 31% quarter-over-quarter growth in net product revenue for PEMGARDA in Q4 2025.
The company ended 2025 with $226.7 million in cash and cash equivalents, boosted by over $200 million raised in financing transactions.
Key developments include the initiation of the DECLARATION Phase 3 pivotal clinical trial for VYD2311 and the nomination of a potential best-in-class RSV antibody, VBY329, for preclinical development.
Revenue Growth
PEMGARDA net product revenue in Q4 2025 grew by 25% year-over-year and 31% quarter-over-quarter.
Cash Position
Ending 2025 cash and cash equivalents stood at $226.7 million, supported by over $200 million raised from financing transactions.
Clinical Trials
DECLARATION Phase 3 pivotal clinical trial of VYD2311 initiated, with top-line data expected in mid-2026.
Fast Track Designation
VYD2311 granted Fast Track designation by the FDA for the prevention of COVID in high-risk individuals.
Pipeline Expansion
Selection of potential best-in-class RSV antibody candidate, VBY329, for preclinical development announced in November 2025.
- Invivyd anticipates significant revenue growth in 2026 fueled by PEMGARDA and potential launches of VYD2311 and VBY329.
- The initiation of the DECLARATION trial marks a crucial step in establishing monoclonal antibody prophylaxis for COVID prevention.
With a robust financial position and promising developments in its pipeline, Invivyd is poised for a transformative year in 2026 as it advances its pivotal programs and expands its portfolio of monoclonal antibodies.